Form 4: Twist Bioscience Director Robert Chess Executes Stock Sale Under 10b5-1 Plan

Director Robert Chess of Twist Bioscience Corp. sold 5,000 shares of common stock at $50 per share on January 7, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Robert Chess, a director at Twist Bioscience Corp, sold 5,000 shares of common stock on January 7, 2025.
• The sale was executed at a price of $50 per share.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted on August 12, 2024.
• Following the transaction, Chess directly owns 16,641 shares of Twist Bioscience Corp.
• Chess also indirectly owns 42,528 shares through the Chess 1997 Trust, where he and his spouse are the sole trustees and beneficiaries.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is part of a pre-planned trading strategy and doesn't necessarily reflect a change in the director's confidence in the company.

Industry Context

Sales by insiders are a normal part of corporate governance. The use of a 10b5-1 plan indicates the sale was pre-planned and not based on any inside information.

Stakeholder Impact

• The sale may have a minor impact on shareholders due to the increased supply of shares, but the pre-planned nature of the sale mitigates concerns about insider information.

Key Dates